Drug Profile
Research programme: lysophosphatidic acid receptor inhibitors - Kirin/Debiopharm
Alternative Names: Debio-0719; Ki16198; Ki16425Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Kirin Brewery
- Class Small molecules
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan
- 21 Apr 2010 Pharmacodynamics data from a preclinical trial in Breast cancer presented at the 101st Annual Meeting of the American Association for Cancer Research ((AACR-2010)
- 30 Jan 2007 DEBIO 0719 licensed to Debiopharm Group worldwide, excluding Asia